Industry News

Lupin Ltd., India's third largest drug maker, on Thursday said it has received approval to market generic version of Allergan Plc's Namenda extended release capsules in US market. Lupin got approval for 7 milligram, 14 mg, 21 mg and 28 mg capsules. Namenda generically called as memantine hydrochloride is used for treatment of moderate to severe dementia of the Alzheimer's type."/>
BRIEF: Lupin gets USFDA nod for generic dementia drug [Mint, New Delhi]
Apollo Hospitals Enterprise Ltd, India's largest healthcare provider, on Thursday said it has entered the medical rehabilitation services business in a joint venture with Italy-based KOS group. The equal joint venture, ApoKos, opened its first 64- bedded medical rehabilitation facility in Hyderabad, built at an estimated cost of Rs.20 crore, excluding land and building expenses. Apollo said the joint venture will be setting up similar medical..."/>
Apollo Hospitals, Italy-based KOS group to set up network of rehab facilities in India [Mint, New Delhi]
Amgen, one of the world's leading biotechnology companies, is teaming with Arrowhead Pharmaceuticals to bring two drugs to market to treat cardiovascular disease in a deal worth more than $50 million to start, with the potential for another $600 million or more in the future. Arrowhead is based in Pasadena, California but most of its research-- including work on these two drugs-- is conducted in Madison, at 465 Science Drive, where the company has about 100 employees."/>
Arrowhead Pharmaceuticals inks drug development deal with Amgen worth up to $673 million [The Wisconsin State Journal]
medical marijuana industry, an obvious question emerges: Where do doctors stand on pot? The medical establishment dismisses weed as scientifically untested, but some individual doctors are breaking ranks to back Amendment 2, the ballot question that will be decided Nov. 8.. The 20,000- member Florida Medical Association opposes Amendment 2."/>
Florida doctors have mixed opinions about medical marijuana [The Palm Beach Post, Fla.]
Unilife Corporation announced today that the Company will not be able to file its audited financial statements by September 30, 2016. As a result, pursuant to rules of the Australian Securities Exchange, trading in the Company's CHESS Depositary Interests on the ASX will be suspended prior to the opening of trading on the ASX on October 3, 2016, or earlier if ASX accepts the Company's request for an immediate voluntary suspension of trading..."/>
Unilife Corporation Provides Trading Update
Delcath Systems, Inc., an interventional oncology company focused on treatments for primary and metastatic liver cancers, today announced that it intends to offer shares of its common stock and warrants to purchase shares of common stock in an underwritten public offering. The completion of the offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual..."/>
Delcath Announces Proposed Public Offering of Common Stock and Warrants
Heska Corporation, a provider of veterinary diagnostic and specialty products, today reported several key executive promotions as part of its ongoing growth initiatives. John McMahon is promoted to Chief Financial Officer. Jason Napolitano continues as Chief Operating Officer and adds the role of Chief Strategist."/>
Heska Announces Executive Promotions to Further Growth Initiatives
SunLink Health Systems, Inc. today announced that its Board of Directors has acted to protect the Company’ s valuable income tax net operating loss carryforwards by adopting a new tax benefits protection rights plan. The purpose of the rights plan is to protect shareholder value by preserving the Company’ s ability to use its NOLs in the future. The rights plan is similar to plans adopted by other public companies with significant net operating losses."/>
SunLink Adopts Shareholder Rights Plan to Protect Tax Benefits
Crescita Therapeutics Inc., a commercial dermatology company with a portfolio of over-the-counter and prescription products for the treatment and care of skin diseases and their symptoms, today announced that Samira Sakhia, President of Knight Therapeutics, has joined its board of directors. Prior to her current role, Ms. Sakhia was the Chief Financial Officer of Paladin Labs."/>
Crescita Therapeutics™ Announces Changes to the Board of Directors
Crescita Therapeutics Inc., a commercial dermatology company with a portfolio of over-the-counter and prescription products for the treatment and care of skin diseases and their symptoms, today announced that Samira Sakhia, President of Knight Therapeutics, has joined its board of directors. Prior to her current role, Ms. Sakhia was the Chief Financial Officer of Paladin Labs."/>
Crescita Therapeutics™ Announces Changes to the Board of Directors
IIROC Trading Halt - AUP (all issues)
MiMedx Group, Inc., the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today the highlights of the Company's participation in the 5 th Congress of World Union Wound Healing Societies held in Florence, Italy..."/>
MiMedx at the 5th Congress of World Union Wound Healing Societies
Exactech, Inc., a developer and producer of bone and joint restoration products for hip, knee, shoulder and spine, today announced positive surgeon feedback on first surgeries performed with the ExactechGPS ® Guided Personalized Surgery system’ s new Total Shoulder Application, which combines preoperative planning with..."/>
Exactech Announces Successful First Surgeries with New ExactechGPS® Total Shoulder Application
WellCare Health Plans, Inc. announced today it appointed H. James Dallas, founder of James Dallas& Associates and former senior vice president of quality and operations for Medtronic, Inc., to its board of directors. "We are delighted to welcome James to our board," said Christian P. Michalik, WellCare's chairman of the board. "He brings strong leadership experience as well as a deep understanding of information technology, risk and change management..."/>
WellCare Appoints H. James Dallas to Board of Directors
Molina Healthcare, Inc. today announced that its plans received ratings from the widely respected National Committee for Quality Assurance as part of the Medicaid Health Insurance Plan Ratings for 2016-2017. The ratings measure Medicaid health plans based on their combined HEDIS ®, CAHPS ® and NCQA Accreditation standards scores. Molina Healthcare’ s health plans in California, Florida, Illinois, Michigan, New Mexico, Ohio, South Carolina, Texas, Utah,..."/>
Molina Healthcare Plans Receive Ratings from NCQA’s Medicaid Health Insurance Plan Ratings 2016-2017
Enanta Pharmaceuticals, Inc.,, a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that a poster presentation on one of the lead compounds in its RSV program was presented today at the 10 th Annual Respiratory Syncytial Virus conference taking place September 28 through October..."/>
Enanta Pharmaceuticals Presents Data on a Novel Non-Fusion Inhibitor of Respiratory Syncytial Virus (RSV) at the 10th Annual Respiratory Syncytial Virus Conference
Histogenics Corporation, a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced the closing of its previously disclosed $30.0 million private placement of common stock, Series A Convertible Preferred Stock and warrants pursuant to a securities purchase agreement. The private placement was led by new healthcare dedicated institutional investors, with participation..."/>
Histogenics Corporation Closes $30.0 Million Private Placement
Prothena Corporation plc, a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, will host a conference call and webcast today at 4:30 PM Eastern Time to discuss its Phase 2 clinical development strategy in psoriatic arthritis for PRX003, an antibody that targets the cellular adhesion..."/>
Prothena Outlines Phase 2 Development Strategy for PRX003
Kite Pharma, Inc. has announced the appointment of Christine Cassiano as Senior Vice President of Corporate Communications and Investor Relations. She will also sit on the company’ s Executive Committee. In this new position, Cassiano will be responsible for transforming Kite’ s communications function to keep pace with the company’ s expanding pipeline of chimeric antigen receptor and T-cell receptor product candidates to treat both hematological..."/>
Kite Pharma Names Christine Cassiano as Senior Vice President of Corporate Communications and Investor Relations
Sangamo BioSciences, Inc., the leader in therapeutic genome editing, announced today that Sandy Macrae, M.B., Ch.B., Ph.D., Sangamo's president and chief executive officer, will participate in the following conferences in October. 2016 Cell& Gene Meeting on the Mesa, La Jolla, CA, October 5-7, 2016 Dr. Macrae will participate in a panel discussion on gene editing at 10:30 am PT on Wednesday, October 5 th, and is scheduled to present a company overview..."/>
Sangamo BioSciences Announces Participation At Upcoming Investor Conferences

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology717 Articles
Consumer Discretionary599 Articles
Financials446 Articles
Industrials392 Articles
Health Care386 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.